Benitec, Tacere deal

Benitec will acquire RNAi company Tacere for about 102.3 million newly issued ordinary shares, which the companies valued at about $1.5 million. The shares represent a 9.5% stake in Benitec. In 2006, Tacere received an exclusive license from Benitec to use its DNA-directed RNAi (ddRNAi) technology for HCV. As part of the deal, which is expected to close this month, Tacere CSO David Suhy will become VP of R&D at Benitec (see BioCentury, Oct. 16, 2006). ...